Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Baron

Showing results (111-120 of 198) with videos related to

Pageof 20
Sort By:
Biomedicines|April 23, 2022
Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor µ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms?Marjorie C Gondré-Lewis, Igor Elman, Tanya Alim, et al.
Biomedical Journal of Scientific & Technical Research|October 30, 2018
Promoting Precision Addiction Management (PAM) to Combat the Global Opioid CrisisKenneth Blum, Edward J Modestino, Jennifer Neary, et al.
Acta Scientific Neurology|August 9, 2024
Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight LossEdward J Modestino, Abdalla Bowirrat, Kai-Uwe Lewandrowski, et al.
Psychology Research and Behavior Management|February 6, 2025
Coupling Bio-Resonance Neurotechnology (BRNT) and Dual Hemispheric Repetitive Transcranial Magnetic Stimulation (rTMS) Reduces Comorbid Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) as Demonstrated by PHQ-9 and GAD-7: Pilot Case SeriesKeerthy Sunder, Milan T Makale, Miles Makale, et al.
Journal of Addiction Psychiatry|August 10, 2023
Psychostimulants for Children: Are We Over or Under Dosing?Kenneth Blum, Catherine Dennen, Paul R Carney, et al.
Acta Scientific Neurology|March 8, 2021
Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?Kenneth Blum, Ali Raza, Tiffany Schultz, et al.
International Journal of Environmental Research and Public Health|January 11, 2022
Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive BehaviorsAshim Gupta, Abdalla Bowirrat, Luis Llanos Gomez, et al.
Current Psychopharmacology|September 1, 2021
Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) <i>via</i> Activation of Neuro-immunological Function in the Face of a Viral PandemicKenneth Blum, Edward J Modestino, David Baron, et al.
Kidney360|January 14, 2025
Establishing Meaningful Patient-Centered Outcomes with Relevance for Patients with Polycystic Kidney Disease: Patient, Caregiver, and Researcher Priorities for Research in Polycystic Kidney DiseaseReem A Mustafa, Hassan Kawtharany, Mohamad A Kalot, et al.
International Journal of Environmental Research and Public Health|September 28, 2021
Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?Kenneth Blum, Mark S Gold, Luis Llanos-Gomez, et al.
Pageof 20

Showing results (111-120 of 198) with videos related to

Sort By:
Pageof 20
Biomedicines|April 23, 2022
Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor µ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms?Marjorie C Gondré-Lewis, Igor Elman, Tanya Alim, et al.
Biomedical Journal of Scientific & Technical Research|October 30, 2018
Promoting Precision Addiction Management (PAM) to Combat the Global Opioid CrisisKenneth Blum, Edward J Modestino, Jennifer Neary, et al.
Acta Scientific Neurology|August 9, 2024
Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight LossEdward J Modestino, Abdalla Bowirrat, Kai-Uwe Lewandrowski, et al.
Psychology Research and Behavior Management|February 6, 2025
Coupling Bio-Resonance Neurotechnology (BRNT) and Dual Hemispheric Repetitive Transcranial Magnetic Stimulation (rTMS) Reduces Comorbid Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) as Demonstrated by PHQ-9 and GAD-7: Pilot Case SeriesKeerthy Sunder, Milan T Makale, Miles Makale, et al.
Journal of Addiction Psychiatry|August 10, 2023
Psychostimulants for Children: Are We Over or Under Dosing?Kenneth Blum, Catherine Dennen, Paul R Carney, et al.
Acta Scientific Neurology|March 8, 2021
Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?Kenneth Blum, Ali Raza, Tiffany Schultz, et al.
International Journal of Environmental Research and Public Health|January 11, 2022
Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive BehaviorsAshim Gupta, Abdalla Bowirrat, Luis Llanos Gomez, et al.
Current Psychopharmacology|September 1, 2021
Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) <i>via</i> Activation of Neuro-immunological Function in the Face of a Viral PandemicKenneth Blum, Edward J Modestino, David Baron, et al.
Kidney360|January 14, 2025
Establishing Meaningful Patient-Centered Outcomes with Relevance for Patients with Polycystic Kidney Disease: Patient, Caregiver, and Researcher Priorities for Research in Polycystic Kidney DiseaseReem A Mustafa, Hassan Kawtharany, Mohamad A Kalot, et al.
International Journal of Environmental Research and Public Health|September 28, 2021
Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?Kenneth Blum, Mark S Gold, Luis Llanos-Gomez, et al.
Pageof 20